GlassScriptPhysician profile
Muhammad Y Jabri
NPI 1285688283
$6,175.55
in general payments reported to CMS, 2019-2025
31 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $286 · 2021: $215 · 2022: $544 · 2023: $1,155 · 2024: $1,656 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,138 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,138.44 |
| Education | $110.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,294.38 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $527.36 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $515.99 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $488.72 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $398.87 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $298.93 | 2019-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $263.50 | 2019-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $257.77 | 2020-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $249.24 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $232.16 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $212.61 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $185.08 | 2020-2025 | Vafseo |
| Glaxosmithkline, LLC. | $155.25 | 2022-2025 | Benlysta, Shingrix |
| Ani Pharmaceuticals, INC. | $144.06 | 2024-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $127.83 | 2023-2025 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $122.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.12 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $113.60 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $75.57 | 2021-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $64.09 | 2019 | |
| Apellis Pharmaceuticals, INC. | $47.41 | 2025 | Empaveli |
| Genzyme Corporation | $45.78 | 2019-2024 | |
| Lilly USA, LLC | $40.88 | 2023-2025 | Jardiance |
| Vantive US Healthcare LLC | $34.56 | 2025 | Renal - Pd |
| Ultragenyx Pharmaceutical INC. | $32.49 | 2019-2021 | |
| Daiichi Sankyo INC. | $31.62 | 2021-2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $29.65 | 2024 | Amvuttra |
| Scpharmaceuticals INC. | $20.14 | 2025 | |
| Shield Therapeutics INC | $17.85 | 2025 | |
| Shire North American Group INC | $16.15 | 2019 | |
| Kyowa Kirin, INC. | $15.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Jabri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.